Published in Biol Psychiatry on November 01, 2004
The role of apolipoprotein E in Alzheimer's disease. Neuron (2009) 5.55
Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 5.55
Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol (2011) 3.56
Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron (2008) 3.08
Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med (2009) 2.87
Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomark Med (2010) 2.17
Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol (2010) 2.16
Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med (2012) 2.01
APOE genotype modulates proton magnetic resonance spectroscopy metabolites in the aging brain. Biol Psychiatry (2013) 1.95
Brain atrophy in healthy aging is related to CSF levels of Aβ1-42. Cereb Cortex (2010) 1.79
Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. Biol Psychiatry (2007) 1.68
Three dimensions of the amyloid hypothesis: time, space and 'wingmen'. Nat Neurosci (2015) 1.60
Identifying and validating biomarkers for Alzheimer's disease. Trends Biotechnol (2010) 1.59
Sex modifies the APOE-related risk of developing Alzheimer disease. Ann Neurol (2014) 1.59
Apolipoprotein E epsilon4 does not modulate amyloid-β-associated neurodegeneration in preclinical Alzheimer disease. AJNR Am J Neuroradiol (2012) 1.57
Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition. Arch Neurol (2012) 1.52
Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings. Arch Neurol (2009) 1.44
Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis. Proc Natl Acad Sci U S A (2012) 1.34
Biomarkers for cognitive impairment and dementia in elderly people. Lancet Neurol (2008) 1.25
The future of blood-based biomarkers for Alzheimer's disease. Alzheimers Dement (2013) 1.22
Cerebrospinal fluid Aβ and tau level fluctuation in an older clinical cohort. Arch Neurol (2012) 1.20
Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models. Free Radic Biol Med (2008) 1.19
Mouse models of Alzheimer's disease. Brain Res Bull (2011) 1.19
Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study. Neurobiol Aging (2010) 1.17
Toward a multifactorial model of Alzheimer disease. Neurobiol Aging (2012) 1.16
The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease. Neurobiol Aging (2007) 1.07
Origins of Alzheimer's disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement. Curr Opin Neurol (2012) 1.04
Apolipoprotein E isoforms and regulation of the innate immune response in brain of patients with Alzheimer's disease. Curr Opin Neurobiol (2011) 1.01
Relationship between CSF biomarkers of Alzheimer's disease and rates of regional cortical thinning in ADNI data. J Alzheimers Dis (2011) 0.99
Children of persons with Alzheimer disease: what does the future hold? Alzheimer Dis Assoc Disord (2008) 0.97
CSF T-Tau/Aβ42 predicts white matter microstructure in healthy adults at risk for Alzheimer's disease. PLoS One (2012) 0.95
Cerebrospinal fluid biomarkers in mild cognitive impairment and dementia. J Alzheimers Dis (2010) 0.93
3alpha-androstanediol, but not testosterone, attenuates age-related decrements in cognitive, anxiety, and depressive behavior of male rats. Front Aging Neurosci (2010) 0.91
ApoE4 induces Aβ42, tau, and neuronal pathology in the hippocampus of young targeted replacement apoE4 mice. Mol Neurodegener (2013) 0.90
CALHM1 P86L polymorphism modulates CSF Aβ levels in cognitively healthy individuals at risk for Alzheimer's disease. Mol Med (2011) 0.90
Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer's disease. Neurobiol Aging (2010) 0.89
Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly. Front Biosci (Landmark Ed) (2013) 0.89
CALHM1 P86L polymorphism does not alter amyloid-beta or tau in cerebrospinal fluid. Neurosci Lett (2009) 0.88
Apolipoprotein E, gender, and Alzheimer's disease: an overlooked, but potent and promising interaction. Brain Imaging Behav (2014) 0.87
Cerebrospinal fluid biomarkers of neurovascular dysfunction in mild dementia and Alzheimer's disease. J Cereb Blood Flow Metab (2015) 0.86
Preclinical Alzheimer disease: identification of cases at risk among cognitively intact older individuals. BMC Med (2012) 0.85
Soluble amyloid-β levels and late-life depression. Curr Pharm Des (2014) 0.84
Somatostatin genetic variants modify the risk for Alzheimer's disease among Finnish patients. J Neurol (2007) 0.83
Measuring Study-Specific Heterogeneity in Meta-Analysis: Application to an Antecedent Biomarker Study of Alzheimer's Disease. Stat Biopharm Res (2010) 0.83
Alzheimer's disease biomarker discovery in symptomatic and asymptomatic patients: experimental approaches and future clinical applications. Exp Gerontol (2009) 0.83
Family history and APOE-4 genetic risk in Alzheimer's disease. Neuropsychol Rev (2012) 0.83
Total ApoE and ApoE4 isoform assays in an Alzheimer's disease case-control study by targeted mass spectrometry (n=669): a pilot assay for methionine-containing proteotypic peptides. Mol Cell Proteomics (2012) 0.82
A non-invasive, rapid method to genotype late-onset Alzheimer's disease-related apolipoprotein E gene polymorphisms. Neural Regen Res (2014) 0.81
Apolipoprotein E highly correlates with AbetaPP- and tau-related markers in human cerebrospinal fluid. J Alzheimers Dis (2008) 0.80
HYDRA: Revealing heterogeneity of imaging and genetic patterns through a multiple max-margin discriminative analysis framework. Neuroimage (2016) 0.79
APOE-by-sex interactions on brain structure and metabolism in healthy elderly controls. Oncotarget (2015) 0.79
The concept of FDG-PET endophenotype in Alzheimer's disease. Neurol Sci (2011) 0.77
The endocytic pathway in microglia during health, aging and Alzheimer's disease. Ageing Res Rev (2016) 0.77
A Unified Approach of Meta-Analysis: Application to an Antecedent Biomarker Study in Alzheimer's Disease. J Appl Stat (2011) 0.75
Exploring Biomarkers for Alzheimer's Disease. J Clin Diagn Res (2016) 0.75
Behavioral testing affects the phenotypic expression of APOE ε3 and APOE ε4 in targeted replacement mice and reduces the differences between them. Alzheimers Dement (Amst) (2015) 0.75
Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins. J Lipid Res (2017) 0.75
Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration. Transl Psychiatry (2017) 0.75
Amyloid Beta and Tau as Alzheimer's Disease Blood Biomarkers: Promise From New Technologies. Neurol Ther (2017) 0.75
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med (2007) 10.00
Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet (2010) 9.20
APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol (2011) 4.80
Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.78
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2011) 4.25
Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA (2003) 4.16
Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care (2010) 4.10
The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement (2010) 3.85
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology (2012) 3.58
Simplified staging for hepatocellular carcinoma. J Clin Oncol (2002) 3.48
Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med (2008) 3.33
Frequency of abnormal carbohydrate metabolism and diabetes in a population-based screening of adolescents. J Pediatr (2005) 3.23
Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement (2010) 2.68
Members of the large Maf transcription family regulate insulin gene transcription in islet beta cells. Mol Cell Biol (2003) 2.64
Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol (2011) 2.41
Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis. Schizophr Bull (2006) 2.34
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2013) 2.32
Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains. Biol Psychiatry (2005) 2.29
Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol (2010) 2.20
Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care (2010) 2.15
Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Sci Transl Med (2012) 2.14
Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol (2010) 2.12
Acute onset of Wegener's granulomatosis and diffuse alveolar hemorrhage treated successfully by extracorporeal membrane oxygenation. Pediatr Crit Care Med (2002) 2.12
Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation (2003) 1.98
Racial and ethnic differences in the relationship between HbA1c and blood glucose: implications for the diagnosis of diabetes. J Clin Endocrinol Metab (2012) 1.87
Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease. Proc Natl Acad Sci U S A (2004) 1.86
A1C: does one size fit all? Diabetes Care (2007) 1.79
Toxoplasma gondii and other risk factors for schizophrenia: an update. Schizophr Bull (2012) 1.75
Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. PLoS One (2011) 1.74
Treatment and outcome of patients with intracystic papillary carcinoma of the breast. Am J Surg (2002) 1.70
Genetic variation in APOL1 associates with younger age at hemodialysis initiation. J Am Soc Nephrol (2011) 1.70
Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy. Arch Ophthalmol (2010) 1.68
CD39 and control of cellular immune responses. Purinergic Signal (2007) 1.68
Treatment of obesity with extension of sleep duration: a randomized, prospective, controlled trial. Clin Trials (2010) 1.67
Severe influenza B myocarditis and myositis. Pediatr Crit Care Med (2004) 1.62
A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology (2006) 1.62
Test-retest stability of the Repeatable Battery for the Assessment of Neuropsychological Status in schizophrenia. Am J Psychiatry (2002) 1.62
Impact of blood collection devices on clinical chemistry assays. Clin Biochem (2009) 1.61
Class B scavenger receptor types I and II and CD36 targeting improves sepsis survival and acute outcomes in mice. J Immunol (2012) 1.61
Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. J Am Coll Cardiol (2005) 1.58
Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem (2009) 1.57
Intensive blood pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial. Diabetes Care (2012) 1.55
Serum amyloid A binding to CLA-1 (CD36 and LIMPII analogous-1) mediates serum amyloid A protein-induced activation of ERK1/2 and p38 mitogen-activated protein kinases. J Biol Chem (2004) 1.55
Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. J Clin Endocrinol Metab (2005) 1.55
Statin attenuates increase in C-reactive protein during estrogen replacement therapy in postmenopausal women. Circulation (2002) 1.53
Evidence for interindividual heterogeneity in the glucose gradient across the human red blood cell membrane and its relationship to hemoglobin glycation. Diabetes (2008) 1.53
Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial. Ann Intern Med (2009) 1.53
Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines. Clin Chem (2005) 1.52
Role of human CD36 in bacterial recognition, phagocytosis, and pathogen-induced JNK-mediated signaling. J Immunol (2008) 1.51
Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement (2009) 1.49
Single-trial discrimination for integrating simultaneous EEG and fMRI: identifying cortical areas contributing to trial-to-trial variability in the auditory oddball task. Neuroimage (2009) 1.49
Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer. Ann Surg Oncol (2003) 1.45
Effect of blood collection tubes on total triiodothyronine and other laboratory assays. Clin Chem (2004) 1.45
Immunoassay interference by a commonly used blood collection tube additive, the organosilicone surfactant silwet L-720. Clin Chem (2005) 1.44
Effects of previous major depressive illness on cognition in Alzheimer disease patients. Am J Geriatr Psychiatry (2005) 1.44
Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. Acta Neuropathol (2010) 1.38
Agreement among glaucoma specialists in assessing progressive disc changes from photographs in open-angle glaucoma patients. Am J Ophthalmol (2008) 1.37
Increased serum levels of heat shock protein 70 are associated with low risk of coronary artery disease. Arterioscler Thromb Vasc Biol (2003) 1.36
Interaction of intracellular beta amyloid peptide with chaperone proteins. Proc Natl Acad Sci U S A (2002) 1.36
Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database. Alzheimers Dement (2010) 1.35
The prevalence of concurrent hearing and vision impairment in the United States. JAMA Intern Med (2013) 1.35
Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol (2012) 1.33
Meta-analysis for genome-wide association study identifies multiple variants at the BIN1 locus associated with late-onset Alzheimer's disease. PLoS One (2011) 1.32
Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med (2002) 1.25
Childhood sexual abuse and adolescent pregnancy: a meta-analytic update. J Pediatr Psychol (2008) 1.25
Association of interatrial block with development of atrial fibrillation. Am J Cardiol (2003) 1.22
HbA1c for the diagnosis of diabetes and prediabetes: is it time for a mid-course correction? J Clin Endocrinol Metab (2010) 1.21
Binding and internalization of lipopolysaccharide by Cla-1, a human orthologue of rodent scavenger receptor B1. J Biol Chem (2003) 1.19
Deletion of cd39/entpd1 results in hepatic insulin resistance. Diabetes (2008) 1.18
Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy. Am J Surg (2007) 1.16
Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer (2004) 1.16
Hemoglobin A1c: teaching a new dog old tricks. Ann Intern Med (2010) 1.13
Sustained low-grade pro-inflammatory state in unmedicated, remitted women with major depressive disorder as evidenced by elevated serum levels of the acute phase proteins C-reactive protein and serum amyloid A. Biol Psychiatry (2006) 1.13
Depression as a risk factor for osteoporosis. Trends Endocrinol Metab (2009) 1.13
Pseudohypoglycemia: a cause for unreliable finger-stick glucose measurements. Endocr Pract (2008) 1.13
CD36 is a novel serum amyloid A (SAA) receptor mediating SAA binding and SAA-induced signaling in human and rodent cells. J Biol Chem (2010) 1.13
Impact on bone of an estrogen receptor-alpha gene loss of function mutation. J Clin Endocrinol Metab (2008) 1.12
Toxicity of a first-generation adenoviral vector in rhesus macaques. Hum Gene Ther (2002) 1.12
Undercorrected refractive error in Singaporean Chinese adults: the Tanjong Pagar survey. Ophthalmology (2004) 1.12
Minimal changes in environmental temperature result in a significant increase in energy expenditure and changes in the hormonal homeostasis in healthy adults. Eur J Endocrinol (2010) 1.11
PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. Eur J Nucl Med Mol Imaging (2005) 1.11
Evening chronotype is associated with changes in eating behavior, more sleep apnea, and increased stress hormones in short sleeping obese individuals. PLoS One (2013) 1.11
Biomarkers in the diagnosis of Alzheimer's disease: are we ready? J Geriatr Psychiatry Neurol (2006) 1.10
Test-retest variability in structural and functional parameters of glaucoma damage in the glaucoma imaging longitudinal study. J Glaucoma (2006) 1.10
CLA-1 and its splicing variant CLA-2 mediate bacterial adhesion and cytosolic bacterial invasion in mammalian cells. Proc Natl Acad Sci U S A (2006) 1.10
Biologic variability in plasma glucose, hemoglobin A1c, and advanced glycation end products associated with diabetes complications. J Diabetes Sci Technol (2009) 1.08
Multi-laboratory testing of a screening method for world trade center (WTC) collapse dust. Sci Total Environ (2007) 1.08
Functional magnetic resonance imaging and magnetoencephalography differences associated with APOEepsilon4 in young healthy adults. Neuroreport (2006) 1.08